In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic impl...
All content for Cures & Capital is the property of Martin Slezak and Simon Birksø and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic impl...
Stephan Christgau on applying the VC mindset in biotech & pharma
Cures & Capital
1 hour 3 minutes
8 months ago
Stephan Christgau on applying the VC mindset in biotech & pharma
How do venture capitalists think? And how do they define and create value in the life science industry? In this episode, we talk to Stephan Christgau, founding partner of Eir Ventures, about the VC mindset, investment decision-making and portfolio strategy. We dive into how VCs assess risk, balance high-stakes opportunities, and what could pharma and biotech companies learn from the VC way of doing things. If you want to connect with us - we would love to hear from you: Linkedin: https://ww...
Cures & Capital
In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic impl...
